Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...gnosis
...le 1. Risk Factors for Multidrug-Resist...
Microbiologic Method...
...DSA suggest noninvasive sampling w...
Noninvasive sampling with semiquantit...
...gest that patients with suspected HAP (...
...markers
...r patients with suspected HAP/VAP,...
...patients with suspected HAP/VAP, ATS and IDSA re...
...tients with suspected HAP/VAP, ATS...
For patients with suspected HAP/VAP, ATS and IDSA...
Treatment
...reatment
...itial
...ients with ventilator-associated tracheobro...
...recommend that all hospitals regularly generat...
...and IDSA recommend that empiric treatment regim...
...patients with suspected VAP, ATS and IDSA r...
...IDSA suggest including an agent act...
...uggest including an agent active against met...
...ic coverage for MRSA is indicated, ATS...
...treatment that includes coverage for...
...d IDSA suggest prescribing two antipseudomonal ant...
...IDSA suggest prescribing one antibioti...
...ith suspected VAP, ATS and IDSA sugg...
...n patients with suspected VAP, ATS and IDSA sug...
...IDSA recommend that empiric antibiotic r...
...IDSA recommend that all hospitals re...
...patients being treated empirically f...
...atients with HAP who are being treated empirica...
...ients with HAP who require empiric...
...r patients with HAP who are being treated empi...
...ents with HAP who are being treated...
...tients with HAP who are being treated...
...with HAP who are being treated empirically, ATS...
...ptimizat...
...s with HAP/VAP, ATS and IDSA suggest th...
...nhaled Antibiotic
...tients with VAP due to Gram-negative bacill...
...n-Specific Therapy
...IDSA recommend that MRSAHAP/VAP be...
...patients with HAP/VAP due to P. aerugi...
...ts with HAP/VAP due to P. aeruginosa, ATS...
For patients with HAP/VAP due to P. aer...
...r patients with HAP/VAP due to P. aeruginosa wh...
...nts with HAP/VAP due to P. aeruginosa, ATS and IDS...
...tients with HAP/VAP due to extended-spec...
...HAP/VAP caused by Acinetobacter specie...
...patients with HAP/VAP caused by Acinetobacter spec...
...nd ATS and IDSA suggest adjunctive inhaled colisti...
...patients with HAP/VAP caused by Acinetobacter...
...ith HAP/VAP caused by Acinetobacte...
...tients with HAP/VAP caused by a carbap...
...ATS and IDSA suggest adjunctive inhaled colistin....
...or patients with VAP, ATS and IDSA reco...
...nts with HAP, ATS and IDSA recommend a 7-day cou...
...ents with HAP/VAP, ATS and IDSA sugges...
...with HAP/VAP, ATS and IDSA suggest us...
...th suspected HAP/VAP, ATS and IDSA...
...le 2. Recommended Initial Empiric Antibi...
...c Treatment Options for Suspected MR...